Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $74.96 million. The enterprise value is $52.05 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 60.21 million shares outstanding. The number of shares has increased by 13.18% in one year.
| Current Share Class | 60.21M |
| Shares Outstanding | 60.21M |
| Shares Change (YoY) | +13.18% |
| Shares Change (QoQ) | +2.10% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 26.89% |
| Float | 59.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.47 |
| Forward PS | 16.43 |
| PB Ratio | 2.51 |
| P/TBV Ratio | 2.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.22, with a Debt / Equity ratio of 0.37.
| Current Ratio | 2.22 |
| Quick Ratio | 2.12 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.69 |
Financial Efficiency
Return on equity (ROE) is -131.15% and return on invested capital (ROIC) is -60.74%.
| Return on Equity (ROE) | -131.15% |
| Return on Assets (ROA) | -50.18% |
| Return on Capital (ROIC) | -60.74% |
| Revenue Per Employee | $179,849 |
| Profits Per Employee | -$841,736 |
| Employee Count | 53 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.39% in the last 52 weeks. The beta is 1.80, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.80 |
| 52-Week Price Change | -49.39% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 1.40 |
| Relative Strength Index (RSI) | 43.10 |
| Average Volume (20 Days) | 971,422 |
Short Selling Information
The latest short interest is 1.78 million, so 2.96% of the outstanding shares have been sold short.
| Short Interest | 1.78M |
| Short Previous Month | 1.95M |
| Short % of Shares Out | 2.96% |
| Short % of Float | 2.98% |
| Short Ratio (days to cover) | 1.54 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $9.53 million and -$44.61 million in losses. Loss per share was -$0.90.
| Revenue | 9.53M |
| Gross Profit | -28.57M |
| Operating Income | -45.64M |
| Pretax Income | -49.97M |
| Net Income | -44.61M |
| EBITDA | -45.23M |
| EBIT | -45.64M |
| Loss Per Share | -$0.90 |
Full Income StatementBalance Sheet
The company has $32.42 million in cash and $9.51 million in debt, giving a net cash position of $22.91 million or $0.38 per share.
| Cash & Cash Equivalents | 32.42M |
| Total Debt | 9.51M |
| Net Cash | 22.91M |
| Net Cash Per Share | $0.38 |
| Equity (Book Value) | 25.37M |
| Book Value Per Share | 0.50 |
| Working Capital | 20.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.26 million and capital expenditures -$64,000, giving a free cash flow of -$38.32 million.
| Operating Cash Flow | -38.26M |
| Capital Expenditures | -64,000 |
| Free Cash Flow | -38.32M |
| FCF Per Share | -$0.64 |
Full Cash Flow StatementMargins
| Gross Margin | -299.67% |
| Operating Margin | -478.80% |
| Pretax Margin | -468.02% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -555.09% |